SOUTH SAN FRANCISCO, Calif.,
Nov. 8, 2021 /PRNewswire/ -- Titan
Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company")
announced that, in a presentation given today at the Society for
Neuroscience 2021 Meeting, Ben Land,
Ph.D., Research Assistant Professor at the University of Washington's Department of
Pharmacology, reported additional positive data from an ongoing in
vivo study of its human kappa-opioid receptor agonist ("TP-2021")
ProNeura®-based implant in an established
5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model.
As previously reported, low dose TP-2021 implants had
demonstrated anti-pruritic effects for up to 2 weeks in this model.
Higher-dose TP-2021 implants were subsequently formulated and the
study repeated after content analysis of the removed low-dose
implants indicated potential drug release duration of approximately
four months, but at levels below the anti-pruritic efficacy
threshold.
A significant reduction in scratching behavior was maintained in
mice who received the high-dose TP-2021 implant at both Day 28 and
Day 56 post-implantation, compared with those that received the
placebo implant, with no safety issues observed. In addition, the
high-dose TP-2021 implant provided sustained supra-therapeutic
plasma levels of TP-2021 through Day 84. As a result, the efficacy
assessment is continuing.
"These results indicate that TP-2021 implants can release drug
above the therapeutic threshold in this mouse pruritus model for
several months following a single treatment," said Dr. Land.
"Difelikefalin (Korsuva™)) intravenous
injection set the guidepost for the treatment of chronic kidney
disease patients undergoing hemodialysis. Demonstration of efficacy
of an oral formulation meant for treating other pruritic
indications, such as atopic dermatitis, has thus far not been
achieved. Titan's ProNeura-based TP-2021 implants present a viable
solution for the delivery of sustained therapeutic levels of a
peripheral kappa agonist for potentially up to 6 months or longer
for the treatment of chronic pruritus and related conditions. A
single administration of TP-2021 using ProNeura implant(s) could
potentially avoid the need for frequent oral administration, even
if a peptide with oral bioavailability can be successfully
developed."
Kate Beebe DeVarney, Ph.D.,
President and Chief Operating Officer of Titan,
commented, "Based on TP-2021's high potency and three-month
post-implantation plasma levels, we believe TP-2021 ProNeura
implants could potentially maintain supra-therapeutic levels for a
prolonged period, and we are looking forward to receiving
additional efficacy and durability data in the coming months."
Marc Rubin, M.D. Titan's
Executive Chairman, added, "These data suggest that a single
administration of TP-2021 implant(s) presents a viable solution for
the long-term, continuous treatment of severe chronic pruritus
associated with certain kidney, liver, and skin conditions."
About Chronic Pruritus
Chronic pruritus is an often debilitating condition, resulting
in the need to scratch that lasts more than 6 weeks. It is a
prevalent symptom associated with a number of serious cutaneous and
systemic conditions. Due to its complex pathogenesis and numerous
contributing factors, effective treatment of chronic pruritus
remains challenging.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development
stage company developing proprietary therapeutics with its
ProNeura® long-term, continuous drug delivery
technology. The ProNeura technology has the potential to be used in
developing products for treating a number of chronic conditions,
where maintaining consistent, around-the-clock blood levels of
medication may benefit the patient and improve medical outcomes.
For more information about Titan, please
visit www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to our
ability to raise capital, the regulatory approval process, the
development, testing, production and marketing of our drug
candidates, patent and intellectual property matters and strategic
agreements and relationships. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
CONTACT:
Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sustained-anti-pruritic-effect-of-titans-tp-2021-implant-reported-today-at-neuroscience-2021-301418931.html
SOURCE Titan Pharmaceuticals, Inc.